ARCT vs MRNA
ARCT: Arcturus Therapeutics is a clinical-stage mRNA company developing liver and respiratory disease therapeutics powered by its proprietary self-amplifying mRNA and lipid nanoparticle delivery platforms. MRNA: Moderna is a pioneer in mRNA technology, working to transform medicine by developing a broad pipeline of prophylactic vaccines and therapeutic medicines.
Side-by-side fundamentals
| Metric | ARCT | MRNA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $12.87 | $197.00 | |
| Market cap | $366M | $78.6B | |
| Net margin FY2025, SEC XBRL | -80.2% | -145.2% | ARCT higher |
| Operating margin FY2025, SEC XBRL | -93.0% | -158.1% | ARCT higher |
| ROE FY2025, SEC XBRL | -30.7% | -32.6% | ARCT higher |
| ROA FY2025, SEC XBRL | -24.3% | -22.9% | MRNA higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.09 | ARCT lower |
| Revenue growth (YoY) as of 2026-09-03 | -76.0% | -27.6% | MRNA higher |
| Revenue CAGR (3y) SEC XBRL | -26.4% | -53.4% | ARCT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.50 | 1.39 | |
| 1-year return as of 2026-10-08 close | -39.3% | +605.6% | MRNA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.